Acurx Pharmaceuticals, Inc. Earnings Recaps
Q3 2025
Nov 12, 2025
Acurx Pharmaceuticals reported significant progress in Q3 2025, marked by a successful reverse stock split, patent grants, and promising updates on its innovative drug pipeline for antibiotic-resistant infections.
Key takeaways
- Achieved compliance with NASDAQ listing requirements post 1-for-20 reverse stock split and met minimum equity thresholds.
- Secured a new patent in Australia for DNA polymerase 3C inhibitors, further strengthening intellectual property portfolio.
- Participated in ID Week to present compelling data on ibezapolstat’s microbiome-sparing properties, reinforcing its efficacy against C. diff infections.
- Published collaborative research in Nature Communications showcasing ibezapolstat’s unique binding conformation to its target, enhancing the scientific foundation for continued development.
- Actively pursuing funding opportunities for a phase three clinical trial program for ibezapolstat, which has FDA QIDP and FAST TRACK designations.